Ligand Pharmaceuticals Incorporated
Ligand Pharmaceuticals Incorporated (LGND): 2 pipeline candidates · 4 upcoming catalysts · ~101 mo cash runway. Updated within the last hour.
BioSniper Score
6-factor signal · derived from public data
100.8 months
D/E 0.54 · 0% dilution
Lead: Approved
2 candidates
4 upcoming, next in ~1905d
0 buys · 74 sells (180d)
A transparent, data-derived signal for Ligand Pharmaceuticals Incorporatedacross cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$5.3B
Cash
$115.1M
Quarterly Burn
$23.0M
Runway
100.8 mo
Revenue
$51.7M
Cash Runway vs Catalysts
A catalyst falls after projected cash runway — potential financing / dilution risk before it hits.
Pipeline (2 candidates)
Upcoming Catalysts (4)
Loss of exclusivity — patent/exclusivity expiry opens the door to generic or biosimilar competition that can erode revenue.
Loss of exclusivity — patent/exclusivity expiry opens the door to generic or biosimilar competition that can erode revenue.
Loss of exclusivity — patent/exclusivity expiry opens the door to generic or biosimilar competition that can erode revenue.
Loss of exclusivity — patent/exclusivity expiry opens the door to generic or biosimilar competition that can erode revenue.
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
353
Total value held
$4.19B
| Holder | Shares | Value |
|---|---|---|
| blackrock, inc. | 2,961,923 | $591.3M |
| janus henderson group plc | 2,019,782 | $403.2M |
| vanguard capital management llc | 1,696,178 | $338.6M |
| vanguard portfolio management llc | 1,100,267 | $219.7M |
| state street corp | 778,856 | $155.5M |
| fmr llc | 596,127 | $119.0M |
| nomura asset management international inc. | 573,312 | $114.5M |
| franklin resources inc | 573,177 | $114.4M |
| geode capital management, llc | 558,934 | $111.6M |
| congress asset management co | 504,637 | $100.8M |
Showing top 10 of 353 institutional holders of Ligand Pharmaceuticals Incorporated. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in Ligand Pharmaceuticals Incorporated's pipeline?
Ligand Pharmaceuticals Incorporated (LGND) has 2 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Ligand Pharmaceuticals Incorporated's lead drug candidate?
Ligand Pharmaceuticals Incorporated's most advanced tracked candidate is capvaxive (Approved) for Dravet Syndrome and Lennox-Gastaut Syndrome.
What is Ligand Pharmaceuticals Incorporated's next catalyst?
Ligand Pharmaceuticals Incorporated's next tracked catalyst is a Patent_Expiry event — "Patent/Exclusivity Expiry: FILSPARI" — expected September 5, 2031.
What is Ligand Pharmaceuticals Incorporated's cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Ligand Pharmaceuticals Incorporated has approximately 100.8 months of cash runway.
What is Ligand Pharmaceuticals Incorporated's market capitalization?
Ligand Pharmaceuticals Incorporated's market capitalization is approximately $5.3B.
Get the full picture on Ligand Pharmaceuticals Incorporated
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.